CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 6 incoming connections
- ScaleMarket cap is $6.27B, above the global median of $1.15B
- PositionReturn on equity is 20%, higher than 95% of its Pharmaceutical Retailers peers (median 8.7%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.51%Above 5Y avg (1.19%)
Annual Rate
BRL 0.46Paid quarterly
Payout Ratio
51.9%Sustainable
Payback Period
39.3 yr
Last Ex-Dividend
Jul 6, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
32.23BBRL6.27B · vs all stocks (USD)
Trailing P/E
21.68xvs Pharmaceutical Retailers peers
Revenue (TTM)
46.53BBRL9.05B · vs all stocks (USD)
Profit Margin
2.89%vs Pharmaceutical Retailers peers
Beta
0.0130xvs all stocks
52-Week Change
3.80%vs all stocks
Forward Annual Dividend Yield
2.51%vs all stocks
Market Capitalization
32.23BBRL6.27B · vs all stocks (USD)
Enterprise Value
38.66BBRL7.52B · vs all stocks (USD)
Trailing P/E
21.68xvs Pharmaceutical Retailers peers
Forward P/E
15.79xvs Pharmaceutical Retailers peers
PEG Ratio
1.38xvs Pharmaceutical Retailers peers
Price to Sales (TTM)
0.6925xvs Pharmaceutical Retailers peers
Price to Book (MRQ)
4.42xvs Pharmaceutical Retailers peers
Enterprise to Revenue
0.8310xvs Pharmaceutical Retailers peers
Enterprise to EBITDA
10.02xvs Pharmaceutical Retailers peers
Gross Margin
33.43%vs Pharmaceutical Retailers peers
Profit Margin
2.89%vs Pharmaceutical Retailers peers
Operating Margin
7.58%vs Pharmaceutical Retailers peers
Return on Assets (TTM)
7.80%vs Pharmaceutical Retailers peers
Return on Equity (TTM)
19.99%vs Pharmaceutical Retailers peers
Revenue (TTM)
46.53BBRL9.05B · vs all stocks (USD)
Revenue per Share (TTM)
28.53BRLUpdated Aug 22, 2026Quarterly Revenue Growth
9.80%vs Pharmaceutical Retailers peers
Gross Profit (TTM)
14.10BBRL2.74B · vs all stocks (USD)
EBITDA (TTM)
3.47BBRL674.75M · vs all stocks (USD)
Net Income (TTM)
1.40BBRL272.96M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.50%vs Pharmaceutical Retailers peers
Operating Cash Flow (TTM)
3.02BBRL587.52M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
2.18BBRL424.06M · vs all stocks (USD)
Forward Annual Dividend Rate
0.4623BRLUpdated Aug 22, 2026Forward Annual Dividend Yield
2.51%vs all stocks
Trailing Annual Dividend Rate
0.4397BRLUpdated Aug 22, 2026Trailing Annual Dividend Yield
2.39%vs all stocks
5-Year Average Dividend Yield
1.19%vs all stocks
Payout Ratio
51.86%vs Pharmaceutical Retailers peers
Minority Interest (Equity)
13.84MBRLFY2025 · Dec 31, 2025Revenue
44.25BBRLFY2025 · Dec 31, 2025Cost of Goods Sold
31.29BBRLFY2025 · Dec 31, 2025Gross Profit
12.96BBRLFY2025 · Dec 31, 2025Operating Income
2.65BBRL515.04M · vs all stocks (USD)
Pre-tax Income
1.45BBRLFY2025 · Dec 31, 2025Income Tax Expense
147.81MBRLFY2025 · Dec 31, 2025Net Income
1.30BBRLFY2025 · Dec 31, 2025EBIT
2.51BBRLFY2025 · Dec 31, 2025EBITDA (Income Statement)
3.46BBRLFY2025 · Dec 31, 2025Selling, General & Administrative
10.29BBRLFY2025 · Dec 31, 2025Other Operating Expenses
28.11MBRLFY2025 · Dec 31, 2025Non-operating Interest Income
0.00BRLFY2025 · Dec 31, 2025Non-operating Interest Expense
1.07BBRLFY2025 · Dec 31, 2025EPS (Basic)
0.7874BRLFY2025 · Dec 31, 2025EPS (Diluted)
0.7820BRLFY2025 · Dec 31, 2025Basic Shares Outstanding
1.65BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.65BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.36BBRLFY2025 · Dec 31, 2025Minority Interests (P&L)
-3.38MBRLFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00BRLFY2025 · Dec 31, 2025Operating Cash Flow
-77.11MBRLFY2025 · Dec 31, 2025Free Cash Flow
-1.48BBRLFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
509.62MBRLFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.36BBRLFY2025 · Dec 31, 2025Stock-based Compensation
27.98MBRLFY2025 · Dec 31, 2025Other Non-cash Items
537.25MBRLFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-754.23MBRLFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.25BBRLFY2025 · Dec 31, 2025Capital Expenditures
-1.40BBRLFY2025 · Dec 31, 2025Net Acquisitions
0.00BRLFY2025 · Dec 31, 2025Other Investing Activity
-3.41MBRLFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.41BBRLFY2025 · Dec 31, 2025Long-term Debt Issuance
1.19BBRLFY2025 · Dec 31, 2025Long-term Debt Payments
-653.87MBRLFY2025 · Dec 31, 2025Common Stock Repurchase
0.00BRLFY2025 · Dec 31, 2025Other Financing Charges
-5.48MBRLFY2025 · Dec 31, 2025Net Financing Cash Flow
530.65MBRLFY2025 · Dec 31, 2025Shares Outstanding
1.75BSharesUpdated Aug 22, 2026Float Shares
1.31BSharesUpdated Aug 22, 2026% Held by Insiders
25.07%vs all stocks
% Held by Institutions
58.04%vs all stocks
Total Cash (MRQ)
652.95MBRL126.95M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.3730BRLUpdated Aug 22, 2026Total Debt (MRQ)
8.59BBRL1.67B · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.18xvs Pharmaceutical Retailers peers
Current Ratio (MRQ)
1.41xvs Pharmaceutical Retailers peers
Book Value per Share (MRQ)
4.17BRLUpdated Aug 22, 2026Total Assets
25.17BBRL4.89B · vs all stocks (USD)
Total Current Assets
14.90BBRLFY2025 · Dec 31, 2025Total Liabilities
17.83BBRLFY2025 · Dec 31, 2025Total Non-current Assets
10.27BBRLFY2025 · Dec 31, 2025Total Non-current Liabilities
7.64BBRLFY2025 · Dec 31, 2025Total Current Liabilities
10.19BBRLFY2025 · Dec 31, 2025Cash
222.23MBRLFY2025 · Dec 31, 2025Cash Equivalents
287.39MBRLFY2025 · Dec 31, 2025Cash & Cash Equivalents
509.62MBRLFY2025 · Dec 31, 2025Other Short-term Investments
19.12MBRLFY2025 · Dec 31, 2025Accounts Receivable
3.40BBRLFY2025 · Dec 31, 2025Inventory
9.58BBRLFY2025 · Dec 31, 2025Accounts Payable
6.91BBRLFY2025 · Dec 31, 2025Short-term Debt
1.53BBRLFY2025 · Dec 31, 2025Other Current Liabilities
482.50MBRLFY2025 · Dec 31, 2025Long-term Debt
7.30BBRLFY2025 · Dec 31, 2025Other Non-current Liabilities
71.45MBRLFY2025 · Dec 31, 2025Common Stock (Book)
4.75BBRLFY2025 · Dec 31, 2025Retained Earnings
0.00BRLFY2025 · Dec 31, 2025Total Shareholders' Equity
7.34BBRL1.43B · vs all stocks (USD)
Treasury Stock
104.08MBRLFY2025 · Dec 31, 202552-Week Low
16.21BRLUpdated Aug 22, 202652-Week High
27.42BRLUpdated Aug 22, 202652-Week Change
3.80%vs all stocks
Beta
0.0130xvs all stocks
50-Day MA
17.94BRLUpdated Aug 22, 2026200-Day MA
21.69BRLUpdated Aug 22, 2026Avg 10-Day Volume
10.85MSharesUpdated Aug 22, 2026Avg 30-Day Volume
9.95MSharesUpdated Aug 22, 2026Diluted EPS (TTM)
0.8500BRLUpdated Aug 22, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 20%, higher than 95% of its Pharmaceutical Retailers peers (median 8.7%)Significant
Return on equity: 0.20Industry median: 0.09Industry P95: 0.17Peers compared: 29.00
Return on assets is 7.8%, higher than 95% of its Pharmaceutical Retailers peers (median 2.9%)Significant
Return on assets: 0.08Industry median: 0.03Industry P95: 0.07Peers compared: 29.00
Financial Health
Altman Z-Score 3.4: safe zoneNotable
Altman Z-Score: 3.40
Supply Chain
Midstream position: 5 outgoing, 6 incoming connectionsNotable
Outgoing: 5.00Incoming: 6.00
High connectivity hub: 11 industry connectionsNotable
Total Connections: 11.00
Scale
Market cap is $6.27B, above the global median of $1.15BNotable
Market cap (USD): 6,265,608,407.142Global Median: 1,146,734,693.424
Revenue is $9.05B, above the global median of $520.53MNotable
Revenue (USD): 9,047,576,278.18Global Median: 520,528,949.311
Levered free cash flow is $424.06M, above the global median of $16.24MNotable
Levered free cash flow (USD): 424,062,718.08Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Victoria's Secret & Co.
Tier 1FlowUnit ReplicationRiskInterface
Installed Building Products Inc.
Tier 1FlowUnit ReplicationProductionInterface
Rush Enterprises Inc.
Tier 1FlowUnit ReplicationInterfaceRisk
Rush Enterprises Inc.
Tier 1FlowUnit ReplicationInterfaceRisk
PriceSmart Inc.
Tier 1FlowUnit ReplicationProductionInterface
AutoNation Inc.
Tier 1FlowUnit ReplicationInterfaceRisk
JD Sports Fashion plc
Tier 1FlowUnit ReplicationRiskInterface
Sprouts Farmers Market Inc.
Tier 1FlowUnit ReplicationInterfaceProduction
President Chain Store Corporation
Tier 1FlowUnit ReplicationInterfaceProduction
Kingfisher plc
Tier 1FlowUnit ReplicationProductionInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Donglai Coating Technology Co., Ltd.
2 interpretationsIndustry-Benchmarked ROA and Margin ElevatedMulti-Year Revenue, Profit, And Income Growth
CSW Industrials Inc.
2 interpretationsIndustry-Benchmarked ROA and Margin ElevatedMulti-Year Revenue, Profit, And Income Growth
Cyrela Brazil Realty S.A. Empreendimentos e Participações
2 interpretationsIndustry-Benchmarked ROA and Margin ElevatedMulti-Year Revenue, Profit, And Income Growth